A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes
Latest Information Update: 24 Jun 2024
Price :
$35 *
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Alveolar soft part sarcoma; Chordoma; Haemangioendothelioma; Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Malignant fibrous histiocytoma; Osteosarcoma; Sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 24 May 2024 Planned End Date changed from 27 Dec 2024 to 27 Dec 2025.
- 24 May 2024 Planned primary completion date changed from 27 Dec 2024 to 27 Dec 2025.
- 18 Oct 2023 Planned End Date changed from 31 Dec 2023 to 27 Dec 2024.